Magic Science Corporation

Magic Science is a South Korean biotechnology company focused on developing innovative drug delivery systems and therapeutic candidates for metabolic diseases. The company specializes in oral peptide delivery technologies designed to improve the bioavailability and stability of peptide-based drugs, which are traditionally administered via injection. Their primary research focus includes the development of oral formulations for GLP-1 and GIP receptor agonists targeting indications such as type 2 diabetes and obesity. By leveraging its proprietary platform, Magic Science aims to provide more convenient and effective treatment options for patients with chronic metabolic conditions.